Adjunctive Bright Light Therapy for Patients With Depression

Status Not yet recruiting

Clinical Trial Summary

The study would enroll depressed adolescents and adults with bipolar I or II disorder or major depressive disorder who are receiving stable psychiatric medication (excluding patients with hypomania or mania, mixed symptoms, or rapid cycling). Participants would be randomly assigned to treatment with either 1,0000-lux bright white light therapy in the morning or 1,0000-lux bright white light therapy in the afternoon, or <100-lux dim red placebo light therapy in the afternoon (N=59 for each group). Participants would be treated for 6 weeks. Symptoms would be assessed every two weeks with the 24-items Hamilton Depression Scale, the Young Mania Rating Scale, and the Pittsburgh Sleep Quality Index; salivary melatonin and cortisol concentrations will be also measured.

Clinical Trial Description

The investigators would divide the participants enrolled into three groups: adjunctive morning bright light therapy (BLT) group (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period of intervention: 7:00~9:00 a.m.), adjunctive afternoon BLT group (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period of intervention: 12:00~14:00 p.m.), adjunctive placebo therapy group (light intensity: <100lux, color: dark red, duration of each intervention session: 30min, time period of intervention: 12:00~14:00 p.m.). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04633707
Study type	Interventional
Source	Guangzhou Psychiatric Hospital
Contact	Lin Kangguang, MD;PHD
Phone	13560360144
Email	linkangguang@163.com
Status	Not yet recruiting
Phase	N/A
Start date	March 2021
Completion date	July 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01316926` - Paxil CR Bioequivalence Study Brazil	Phase 1
Recruiting	`NCT06187454` - Transcranial Direct Current Stimulation for Depression	N/A
Completed	`NCT04469322` - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression	N/A
Recruiting	`NCT05768126` - Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine	Phase 4
Completed	`NCT03219879` - Telephone-administered Relapse Prevention for Depression	N/A
Recruiting	`NCT06038721` - Unified Protocol: Community Connections	N/A
Completed	`NCT03043560` - Study to Treat Major Depressive Disorder With a New Medication	Phase 2
Completed	`NCT04091139` - Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong	Phase 2/Phase 3
Completed	`NCT00069459` - Seasonal Affective Depression (SAD) Study	Phase 1
Recruiting	`NCT05503966` - Combining Antidepressants and Attention Bias Modification in Depression	N/A
Recruiting	`NCT03001245` - Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents	N/A
Completed	`NCT02939560` - TMS for Adults With Autism and Depression	N/A
Completed	`NCT02452892` - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)	N/A
Completed	`NCT02542891` - European Comparative Effectiveness Research on Internet-based Depression Treatment	N/A
Completed	`NCT02224508` - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks	N/A
Completed	`NCT02306551` - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Withdrawn	`NCT02238730` - Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy	N/A
Completed	`NCT01597661` - Bupropion & Cardio Birth Defect (Slone)	N/A
Completed	`NCT01407575` - Buprenorphine for Treatment Resistant Depression	Phase 3
Completed	`NCT01093053` - Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations	N/A